Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1 1

Status

Unknown 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Melanoma 10Carcinoma, Renal Cell 9Kidney Neoplasms 7Leukemia, Myeloid, Chronic-Phase 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia 6Lymphoma 5Multiple Myeloma 4Lymphoma, Follicular 4Lymphoma, Mantle-Cell 3Rectal Neoplasms 2Neoplasms, Plasma Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasms 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Hodgkin Disease 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Rituximab 23Cyclophosphamide 11Radiotherapy 8Prednisone 8Vincristine 7Doxorubicin 7Lenalidomide 6Bendamustine Hydrochloride 5Chlorambucil 4Peripheral Blood Stem Cell Transplantation 3Filgrastim 3obinutuzumab 2liposomal amphotericin B 2idelalisib 2ibrutinib 2fludarabine phosphate 2VAP-cyclo protocol 2Therapeutics 2Psychiatric Rehabilitation 2Levofloxacin 2Interferon-alpha 2Idarubicin 2Epoetin Alfa 2Early Intervention, Educational 2Cyclosporine 2Busulfan 2zanubrutinib 1tafasitamab 1parsaclisib 1orelabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, B-Cell, Marginal Zone × Interferon-alpha × Clear all
NCT00003639 2013-09-17

Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 3 Unknown
200 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT00003924 2013-08-07

Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 3 Unknown
360 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡